cisplatin + cyclophosphamide + doxorubicin + lomustine + methotrexate + mitomycin

This is a combination chemotherapy regimen consisting of six cytotoxic agents, each with distinct mechanisms of action. The combination is not a standard or widely recognized regimen in oncology, and there are no established clinical trials or published studies specifically evaluating this exact six-drug combination as a single protocol. Each drug individually is used in various cancer treatments, but their combined use as listed here is not described in major oncology literature or guidelines. **Mechanisms of Action:** - **Cisplatin:** Platinum-based alkylating agent that forms DNA crosslinks, inhibiting DNA replication and transcription. - **Cyclophosphamide:** Alkylating agent that introduces alkyl groups into DNA bases, causing DNA strand breaks and cell death. - **Doxorubicin:** Anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, leading to double-strand breaks. - **Lomustine:** Nitrosourea alkylating agent that crosslinks DNA and RNA strands. - **Methotrexate:** Antimetabolite that inhibits dihydrofolate reductase (DHFR), blocking folate metabolism required for nucleotide synthesis. - **Mitomycin C (mitomycin):** Bioreductive alkylating agent activated intracellularly to form crosslinks between complementary strands of DNA. **Indication/Use:** There are no approved indications for this specific six-drug combination. Each component has been used in various cancer types (e.g., breast cancer, lymphoma, lung cancer) but not together as described[1][2][4].